Ashleigh Palmer, co-founder of Provention and its CEO, is a life sciences industry entrepreneur and innovator with more than 30 years experience and expertise in corporate strategy formulation, preclinical and clinical drug evaluation and product development and commercialization. During his career, Mr. Palmer has served as CEO for multiple biopharma companies (both private and public) and has held numerous board director and chairman positions. In addition to leading Provention, Mr. Palmer currently serves as Chairman of Celimmune, LLC, a clinical stage immunotherapy company dedicated to developing transformational therapies for celiac disease and other serious immune-mediated diseases, and as a non-executive director of Third Pole, a clinical-stage biopharmaceutical company developing electric generated inhaled nitric oxide. Mr. Palmer is also President and Founder of Creative BioVentures™ Corp. (CBV), a strategic advisory firm serving the biopharma industry.
Prior to founding Provention, Celimmune and CBV Mr. Palmer was Vice President, Business Development for British Oxygen’s Ohmeda Pharmaceutical Products, Inc., where he was instrumental in its sale to a consortium led by Baxter International Inc. by spinning out the company’s inhaled nitric oxide assets as INO Therapeutics, Inc. (now Ikaria/Mallinckrodt). Under his leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world’s first selective pulmonary vasodilator, INOmax®, acquired by Mallinckrodt in 2015 for $2.3 billion. Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing leadership at Reckitt Benckiser. Educated in the UK, Mr. Palmer received his MBA from the University of Bradford and his B.Sc. honors in Biochemistry and Applied Molecular Biology from the University of Manchester.